Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial

Status Not yet recruiting

Clinical Trial Summary

COIN trial is a a prospective, randomized, placebo-controlled, double-blind, multicenter clinical study. Approximately 230 patients with small abdominal aortic aneurysms (AAA) will be randomly allocated to low-dose colchicine group or placebo group. All study patients will be followed up in the outpatient clinic every 3 months and undergo CTA scans after 24 months from randomization. The primary objective is to test the hypothesis that low dose colchicine can inhibit the progression of AAA diameter. The secondary objective is to test the hypothesis that low dose colchicine can inhibit the progression of AAA volume, reduce the incidence of clinical outcomes associated with AAA, reduce the incidence of major adverse cardiovascular events and all-cause mortality.

Clinical Trial Description

This study is a prospective, randomized, placebo-controlled, double-blind, multicenter clinical study to test the research hypothesis that low-dose colchicine (0.5 mg/d) can delay the progression of AAA. The study will enroll patients with infrarenal abdominal aortic aneurysms with a maximum diameter of 30-50 mm and no indication for surgical or endovascular treatment. All patients will receive the best standard medical treatment. Before randomization, all patients will undergo a 1-month lead-in period, during which open-label colchicine 0.5 mg/d will be administered. If there is colchicine intolerance, they will not be randomized. The study center performed computer-generated block randomization (block size 8). Randomization method and block size will not unblinded until all data analyses are completed. Enrolled patients will randomly assigned to each hospital in a 1:1 ratio by the randomization center through sequentially coded, sealed, light-tight envelopes, to colchicine and placebo groups. After randomization, patients will receive low-dose colchicine (0.5 mg/d) or placebo, respectively, and will be followed up for 24 months. We will evulate whether low-dose colchicine can delay the progression of AAA by assessing the change in maximum aneurysm diameter by CTA. At the same time, its effects on abdominal aortic aneurysm-related and cardiovascular-related clinical events will be observed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05361772
Study type	Interventional
Source	Guangdong Provincial People's Hospital
Contact	Songyuan Luo, MD
Phone	+86-13570337597
Email	656781257@qq.com
Status	Not yet recruiting
Phase	N/A
Start date	June 1, 2022
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04227054` - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks	N/A
Active, not recruiting	`NCT03687489` - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System	N/A
Active, not recruiting	`NCT03507413` - Metformin Therapy in Non-diabetic AAA Patients	Phase 2/Phase 3
Not yet recruiting	`NCT05756283` - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair	N/A
Not yet recruiting	`NCT04089241` - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair	N/A
Active, not recruiting	`NCT02604303` - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Terminated	`NCT01843335` - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair	N/A
Completed	`NCT02229006` - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms	N/A
Completed	`NCT02224794` - LIFE Study: Least Invasive Fast-Track EVAR
Terminated	`NCT02469376` - Evaluation of a New Imagingtechnologie for Thrombosis	Phase 1
Completed	`NCT01118520` - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)	Phase 2
Terminated	`NCT01425242` - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension	N/A
Completed	`NCT00746122` - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair	N/A
Completed	`NCT03952780` - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed	`NCT00583414` - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients	N/A
Recruiting	`NCT05864560` - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed	`NCT01683084` - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms	Phase 4
Active, not recruiting	`NCT03180996` - Global Fenestrated Anaconda Clinical sTudy
Completed	`NCT02493296` - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed	`NCT03320408` - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial — COIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms